Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) besides received a bullish standing update from Stifel connected February 11, with the steadfast raising the terms people connected the banal to $120 from $119 portion maintaining a Buy standing and noting that it anticipates a “quiet(ish)” archetypal half. However, it inactive likes the longer-term, ex-Jakafi foundation.

The bullish standing updates came aft Incyte Corporation (NASDAQ:INCY) announced fiscal results for fiscal Q4 and the afloat twelvemonth ended December 31, 2025, connected February 10, reporting a full gross of $1.51 cardinal for the quarter, up 28% compared to the anterior twelvemonth period. Management attributed the maturation to an summation successful full nett merchandise gross and milestone and declaration revenue. Total gross for the afloat twelvemonth reached $5.14 billion, reflecting a maturation of 21% compared to the anterior twelvemonth play and chiefly driven by maturation successful the full nett merchandise gross and milestone and declaration revenue.

Incyte Corporation (NASDAQ:INCY) is simply a biopharmaceutical institution that discovers, develops, and commercializes proprietary therapeutics, focusing connected oncology, hematology, inflammation, and autoimmunity therapeutic areas.

While we admit the imaginable of INCY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.